(lp0
S'The Main Reason Achillion Pharmaceuticals, Inc. Collapsed 34% in November Motley Fool - Dec 5, 2016 Shares of Achillion Pharmaceuticals , a developmental-stage developer of small-molecule drugs to treat autoimmune diseases and infectious diseases such as hepatitis C, plummeted 34% in November, according to data from S&amp;P Global&nbsp;...Achillion Pharma  Announces Presentation of Novel Research Related to ... - StreetInsider.com'
p1
aS'BRIEF-Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 ... Reuters - Feb 23, 2017 LONDON, March 10 Investors expect the European Central Bank to raise interest rates by March 2018, money market prices show, with some banks forecasting multiple hikes in 2018 on expectations the central bank will wind down stimulus as the European&nbsp;...'
p2
aS'Achillion Pharmaceuticals - Taking Its First Steps After HCV Seeking Alpha - Dec 25, 2016 Achillion Pharmaceuticals, Inc.  is a clinical stage biopharmaceutical company with drugs being developed primarily in the hepatitis C virus and complement factor pathway disease areas.'
p3
aS'Achillion Pharmaceuticals Inc.  Plunges 9.34% on February 16 Equities.com - Feb 16, 2017 Achillion Pharmaceuticals Inc.  had a rough trading day for Thursday February 16 as shares tumbled 9.34%, or a loss of $-0.44 per share, to close at $4.27.Achillion Pharmaceuticals Inc  Stock Technicals Hit Weakness - CML NewsEarnings Roundup: Achillion Pharmaceuticals, Inc.  - FactsReporter'
p4
aS'Stock Update : Achillion Pharmaceuticals, Inc. Announces $15 ... Smarter Analyst - Dec 28, 2016 Achillion Pharmaceuticals, Inc.  announced that it has received a $15 million milestone payment from Janssen Research &amp; Development, LLC.Jason S. Fisherman Acquires 10000 Shares of Achillion Pharmaceuticals Inc ... - Sports PerspectivesHot Biotech Stocks To Watch Right Now: Cempra, Inc. , Achillion ... - The Independent Republic'
p5
aS'Why Achillion Pharmaceuticals Jumped 10% in May Motley Fool - Jun 2, 2016 What: After reporting first-quarter financials, updating investors on its clinical trial progress, and initiating a new phase 2b hepatitis C trial, Achillion Pharmaceuticals, Inc.  saw its shares rally by 10% last month, according to S&amp;P ...'
p6
aS'Achillion Pharmaceuticals, Inc.  Provides 3Q:16 Update; Shares Fall 19% Smarter Analyst - Nov 3, 2016 ACHN Achillion Pharmaceuticals, Inc.  reported financial results for the three months ended September 30, 2016.'
p7
aS'Achillion Pharmaceuticals Inc.  Settles Into New 52-Week Low on February ... Equities.com - Feb 24, 2017 Shares of Achillion Pharmaceuticals Inc.  sank into a new 52-week low yesterday, and could be a company to watch at the open.'
p8
aS'Why Achillion Pharmaceuticals Is Down Big in 2016 Motley Fool - Jun 20, 2016 What: Despite co-developer Johnson &amp; Johnson  making progress on developing next-generation therapies for hepatitis C, shares in Achillion Pharmaceuticals  have tumbled 15.6% so far this year, according to S&amp;P Global&nbsp;...'
p9
aS'Company Update : Achillion Pharmaceuticals, Inc. Announces ... Smarter Analyst - Sep 23, 2016 Achillion Pharmaceuticals, Inc.  announced that updated interim results were presented today in an ePoster describing a phase 2 study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies  at&nbsp;...'
p10
a.